OBJECTIVE: Lithium carbonate (Li) or divalproex sodium (DVPX) may be effective for some juveniles with bipolar disorder. Many youths with bipolar disorder do not respond to DVPX or Li monotherapy. An open-label study was conducted to examine the effectiveness of combination DVPX and Li therapy with youths diagnosed with bipolar disorder. METHOD: Patients meeting DSM-IV criteria for bipolar I or bipolar II disorder, ages 5 to 17 years, were treated prospectively for up to 20 weeks with DVPX + Li. Assessments included the Young Mania Rating Scale (YMRS), Children's Depression Rating Scale-Revised (CDRS-R), and the Children's Global Assessment Scale (CGAS). The a priori definition of clinical remission utilized included four contiguous weekly ratings of YMRS </=12.5, CDRS-R </=40, CGAS >/=51, clinical stability, and no evidence of mood cycling. RESULTS: Ninety patients (66 males, 24 females) were treated. Significant improvement (p <.0001) in all outcome measures was observed by week 8 as well as at the end of study. The mean time in study was 11.3 weeks. Forty-seven percent (n = 42) met a priori criteria for remission. CONCLUSIONS: Symptoms of mania and depression in juvenile bipolar disorder may be safely and effectively treated acutely with DVPX + Li.
OBJECTIVE:Lithium carbonate (Li) or divalproex sodium (DVPX) may be effective for some juveniles with bipolar disorder. Many youths with bipolar disorder do not respond to DVPX or Li monotherapy. An open-label study was conducted to examine the effectiveness of combination DVPX and Li therapy with youths diagnosed with bipolar disorder. METHOD:Patients meeting DSM-IV criteria for bipolar I or bipolar II disorder, ages 5 to 17 years, were treated prospectively for up to 20 weeks with DVPX + Li. Assessments included the Young Mania Rating Scale (YMRS), Children's Depression Rating Scale-Revised (CDRS-R), and the Children's Global Assessment Scale (CGAS). The a priori definition of clinical remission utilized included four contiguous weekly ratings of YMRS </=12.5, CDRS-R </=40, CGAS >/=51, clinical stability, and no evidence of mood cycling. RESULTS: Ninety patients (66 males, 24 females) were treated. Significant improvement (p <.0001) in all outcome measures was observed by week 8 as well as at the end of study. The mean time in study was 11.3 weeks. Forty-seven percent (n = 42) met a priori criteria for remission. CONCLUSIONS: Symptoms of mania and depression in juvenile bipolar disorder may be safely and effectively treated acutely with DVPX + Li.
Authors: Keming Gao; David E Kemp; Zuowei Wang; Stephen J Ganocy; Carla Conroy; Marry Beth Serrano; Martha Sajatovic; Robert L Findling; Joseph R Calabrese Journal: Psychopharmacol Bull Date: 2010
Authors: Michael Strober; Boris Birmaher; Neal Ryan; David Axelson; Sylvia Valeri; Henrietta Leonard; Satish Iyengar; Mary Kay Gill; Jeffrey Hunt; Martin Keller Journal: Bipolar Disord Date: 2006-08 Impact factor: 6.744
Authors: Robert L Findling; Vivian Kafantaris; Mani Pavuluri; Nora K McNamara; Jon McClellan; Jean A Frazier; Linmarie Sikich; Robert Kowatch; Jacqui Lingler; Jon Faber; Brieana M Rowles; Traci E Clemons; Perdita Taylor-Zapata Journal: J Child Adolesc Psychopharmacol Date: 2011-06 Impact factor: 2.576
Authors: Eric Youngstrom; Joan Zhao; Raymond Mankoski; Robert A Forbes; Ronald M Marcus; William Carson; Robert McQuade; Robert L Findling Journal: J Child Adolesc Psychopharmacol Date: 2013-03-12 Impact factor: 2.576